NCT04692103View on ClinicalTrials.gov

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

July 10, 2021

Primary Completion Date

October 1, 2021

Study Completion Date

April 30, 2041

Conditions
Estrogen Receptor PositivePrimary or Recurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
Interventions
DRUG

F-18 16 Alpha-Fluoroestradiol

Undergo F-18 FES PET/CT

PROCEDURE

Positron Emission Tomography

Undergo F-18 FES PET/CT

PROCEDURE

Computed Tomography

Undergo F-18 FES PET/CT

DRUG

Fludeoxyglucose F-18

Undergo FDG PET/CT

PROCEDURE

Positron Emission Tomography

Undergo FDG PET/CT

PROCEDURE

Computed Tomography

Undergo FDG PET/CT

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

University of Washington

OTHER